

---

## ...BIBLIOGRAPHY...

- Abram WP, Baum M, Berstock DA, et al. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer: Preliminary analysis by the CRC Adjuvant Breast Trial Working Party. *Br J Cancer* 1988;57:604-607.
- Assikis VJ, Neven P, Jordan VC, et al. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. *Eur J Cancer* 1996;32A:1464-1476.
- Bagdade JD, Wolter J, Subbaiah PV, et al. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. *J Clin Endocrinol Metab* 1990;70:1132-1135.
- Baker MS, Kessler LG, Urban N, et al. Estimating the treatment costs of breast and lung cancer. *Med Care* 1991;29:40-48.
- Barrett-Conner E. The economic and human costs of osteoporotic fracture. *Am J Med* 1995;98(suppl 2A):3S-8S.
- Bernstein SJ, Kosecoff J, Gray D, Hampton JR, Brook RH. The appropriateness of the use of cardiovascular procedures. British versus U.S. perspectives. *Inter J Technol Assess in Health Care* 1993; 9:3-10.
- Bertelli G, Pronzato P, Amoroso D, et al. Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels. *Breast Cancer Res Treat* 1988;12:307-310.
- Bourassa MG, Gurne O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. *J Am Coll Cardiol* 1993;22(suppl A):14A-19A.
- Brainsky A, Glick H, Lydick E, et al. The economic cost of hip fractures in community-dwelling older adults: A prospective study. *J Am Geriatr Soc* 1997;45:281-287.
- Breast Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 1998.
- Breast Cancer Trials Committee, Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. *Lancet* 1987;2:171-175.
- Breen N, Kessler LG, Brown ML. Breast cancer control among the underserved: An overview. *Breast Cancer Res Treat* 1996;40:105-115.
- Briziarelli G. Effects of dosage and time of administration of testosterone propionate on 7,12-dimethylbenzanthracene mammary carcinogenesis in the rat. *Z Krebsforsch* 1965;66:517-522.
- Brophy JM, Joseph L. Placing trials in context using Bayesian analysis: GUSTO revisited by Reverend Bayes. *JAMA* 1995;273:871-875.
- Brown ML. Sensitivity analysis in the cost-effectiveness of breast cancer screening. *Cancer* 1992;69:1963-1967.
- Brown ML. The national economic burden of cancer: An update. *J Natl Cancer Inst* 1990;82:1811-1814.
- Bruning PF, Bonfrer JM, Hart AA, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. *Br J Cancer* 1988;58:497-499.
- Bryson HM, Plosker GL. Tamoxifen: A review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer. *Pharmacoeconomics* 1993;4:40-66.
- Butler JRG, Furnival CM, Hart RFG. The costs of treating breast cancer in Australia and the implications for breast cancer screening. *Aust N Z J Surg* 1995;65:485-491.
- Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 1998.
- Cancer facts and figures-1996. National Cancer Institute, National Institutes of Health. <http://www.cancer.org/statistics/96eff/cost.html>.
- Cancer facts. National Cancer Institute. National Institutes of Health. 1998. <http://198.77.70.12/1-1.htm>.
- Cancer Rates and Risks. 4th ed. Bethesda, MD: National Cancer Institute; 1994.
- Carter AP, Thompson RS, Bourdeau RV, et al. A clinically effective breast cancer screening program can be cost-effective too. *Prev Med* 1987;16:19-34.
- Chassin MR, Kosecoff J, Solomon DH, Brook RH. How coronary angiography is used. Clinical determinants of appropriateness. *JAMA* 1987;258:2543-2547.
- Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. *Bone* 1994;15:377-386.
- Clancy T, Kitchen S, Churchill P, et al. DRG reimbursement: Geriatric hip fractures in the community hospital trauma center. *Southern Med J* 1998;91:457-461.
- Cuzick J, Allen D, Baum M, et al. Long-term effects of tamoxifen. *Eur J Cancer* 1993;22:87-94.

---

...BIBLIOGRAPHY...

- Damoiseaux RA, van Balen FA, Hoes AW, de Melker RA. Antibiotic treatment of acute otitis media in children under two years of age: Evidence based? *Br J Gen Pract* 1998;48(437):1861-1864.
- Dao TL. The role of ovarian hormones in initiating the induction of mammary cancer in rats by polynuclear hydrocarbons. *Cancer Res* 1962;22:973-981.
- Desch CE, Hillner BE, Smith TJ, et al. Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. *J Clin Oncol* 1993; 11:777-782.
- Dorsey JH, Holtz PM, Griffiths RI, et al. Costs and charges associated with three alternative techniques of hysterectomy. *N Engl J Med* 1996;335:476-482.
- Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. *JAMA* 1998;279:458-462.
- Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. *Lancet* 1998;351:1451-1467.
- Eddy DM, Hasselblad V, McGivney W, Hardee W. The value of mammography screening in women under age 50 years. *JAMA* 1988;259:1512-1519.
- Elixhauser A. Costs of breast cancer and the cost-effectiveness of breast cancer screening. *Intl J Tech Assess Health Care* 1991;7:604-615.
- Fendrick AM, Ridker PM, Bloom BS. Improved health benefits of increased and expanded utilization of thrombotic therapy. *Arch Intern Med* 1994;154:1605-1609.
- Finkel ML, Finkel DJ. The effect of a second opinion program on hysterectomy performance. *Med Care* 1990;28:776-783.
- Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. *Health Care Fin Rev* 1997;18:51-76.
- Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. *N Engl J Med* 1989; 320:479-484.
- Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. *J Natl Cancer Inst* 1994;86:527-537.
- Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J Natl Cancer Inst* 1998;90:1371-1388.
- Fisher B, Redmond C. New perspective on cancer of the contralateral breast: A marker for assessing tamoxifen as a preventive agent. *J Natl Cancer Inst* 1991;83:1278-1280.
- Fisher B. A commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. *J Clin Oncol* 1996;14:1027-1039.
- Fornander T, Rutqvist LE, Sjöberg HE, et al. Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women. *J Clin Oncol* 1990;8:1019-1024.
- Foulkes WD, Wong N, Brunet JS, et al. Germ-line BCRA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. *Clin Cancer Res* 1997;3(12 pt 1): 2565-2569.
- Fuchs VR, Zeckhauser R. Valuing health: A "priceless" commodity. *Am Econ Rev* 1987;77:263-268.
- Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. *J Natl Cancer Inst* 1989;81:1879-1886.
- Garner TI, Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. *Med Care* 1987;25:25-34.
- Gold MR, Siegel JE, Russell LB, Weinstein MC. *Cost-Effectiveness in Health and Medicine*. New York, NY: Oxford University Press; 1996.
- Gortmaker SL, Bickford AF, Mathewson HO, Dumbaugh K, Tirrell PC. A successful experiment to reduce unnecessary laboratory use in a community hospital. *Med Care* 1988;26:631-642.
- Graboyes TB, Biegelsen B, Lampert S, Blatt CM, Lown B. Results of a second-opinion trial among patients recommended for coronary angiography. *JAMA* 1992; 268:2537-2540.

---

...BIBLIOGRAPHY...

- Greenwood M, Henritze J. Coorscreen: A low-cost, on-site mammography screening program. *Am J Health Promot* 1996;10:364-370.
- Grupo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardio. Gissi-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. *Lancet* 1992;339:753-770.
- Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modeling practices: A suggested framework. *Value in Health* 1998;1:131-147.
- Halpern MT, Palmer CS, Seidlin M. Treatment patterns for otitis externa. *J Am Board Fam Pract* 1999;12:1-7.
- Hawkins DW, Langley PC, Krueger KP. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery. *Clin Ther* 1998;20:182-195.
- Henderson IC. Adjuvant systemic therapy for early breast cancer. *Cancer* 1994;74(suppl 1):401-409.
- Henson DE, Ries LA, Carriaga MT. Conditional survival of 56,268 patients with breast cancer. *Cancer* 1995;76:237-242.
- Hillman AL, Kim MS. Economic decision making in healthcare: A standard approach to discounting health outcomes. *Pharmacoeconomics* 1995;7:198-205.
- Hillner BE, Smith TJ, Desch CE. Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model. *Breast Cancer Res Treat* 1993;25:97-105.
- Hillner BE, Smith TJ. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. *N Engl J Med* 1991;324:160-168.
- Hillner BE, Smith TJ. Should women with node-negative breast cancer receive adjuvant chemotherapy? Insights from a decision analysis model. *Breast Cancer Res Treat* 1992;23:17-27.
- Holmes MH, Hunter DEJ, Colditz GA, et al. Association of dietary intake of fat and fatty acids with risks of breast cancer. *JAMA* 1999;281:914-920.
- Hu R, Mustard CA, Burns C. Epidemiology of incident spinal fracture in a complete population. *Spine* 1996;21:492-499.
- Hutton J, Brown R, Borowitz M, et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. *Pharmacoeconomics* 1996;9(suppl 2):8-22.
- Johnell O. The socioeconomic burden of fractures: Today and in the 21st century. *Am J Med* 1997;103(2A):20S-26S.
- Jordan VC, Allen KE. Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxy-tamoxifen in the DMBA-induced rat mammary carcinoma model. *Eur J Cancer* 1980;16:239-251.
- Jordan VC, Dix CJ, Allen KE. The effectiveness of long-term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Jones SE, Salmon SE, eds. *Adjuvant Therapy of Cancer II*. New York, NY: Grune and Stratton; 1979:19-26.
- Jordan VC, Fritz NF, Tormey DC. Long-term adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin and antithrombin III. *Cancer Res* 1987;47:4517-4519.
- Jordan VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma. *Eur J Cancer* 1976;12:419-424.
- Kramer AM, Steiner JF, Schlenker RE, et al. Outcomes and costs after hip fracture and stroke: A comparison of rehabilitation settings. *JAMA* 1997;277:396-404.
- Legorreta AP, Brooks RJ, Leibowitz AN, et al. Cost of breast cancer treatment: A 4-year longitudinal study. *Arch Intern Med* 1996;156:2197-2201.
- Lipscomb J, Weinstein MC, Torrance GW. 1996: Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. *Cost-effectiveness in Health and Medicine*. New York, NY: Oxford University Press; 1996:214-246.
- Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. *N Engl J Med* 1992;326:852-856.
- Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. *J Natl Cancer Inst* 1990;82:1327-1332.
- Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. *Ann Intern Med* 1991;115:860-864.

---

## ...BIBLIOGRAPHY...

- Magaziner J, Lydick E, Hawkes W, et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. *Am J Public Health* 1997;87:1630-1636.
- Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. *N Engl J Med* 1995;332:1418-1424.
- McCarthy EG, Finkel ML. Second consultants' opinion for elective gynecological surgery. *Obstet Gynecol* 1980;403.
- McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. *Br Med J* 1995;311:977-980.
- Menzin J, Colditz GA, Regan MM, et al. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. *Arch Intern Med* 1995;155:757-764.
- *Mosby's GenRx*, 8th ed. St. Louis, MO: Mosby-Year Book; 1998.
- Muñoz E, Shamash F, Friedman M, et al. Lumpectomy vs mastectomy: The costs of breast preservation for cancer. *Arch Surg* 1986;121:1297-1301.
- Mushinski M. Hysterectomy charges: Geographic variations United States, 1994. *Stat Bull* 1996;77:2-12.
- Mushinski M. Variations in average charges for strokes and TIAs: United States, 1995. *Stat Bull* 1997;78:9-18.
- Neal AJ, Evans K, Hoskin PJ. Does long-term administration of tamoxifen affect bone mineral density? *Eur J Cancer* 1993;29A:1971-1973.
- Perrier A, Buswell L, Bounameaux H, et al. Cost-effectiveness of noninvasive diagnostic aids in suspected pulmonary embolism. *Arch Int Med* 1997;157:2309-2316.
- Plans-Rubio P. Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease. *Pharmacoeconomics* 1998;13(Part 2):623-643.
- Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. *Lancet* 1998;352:98-101.
- Powles TJ, Jones AL, Ashley SE, et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. *Breast Cancer Res Treat* 1994;31:73-82.
- Pritchard KI. Is tamoxifen effective in prevention of breast cancer? *Lancet* 1998;352:80-81.
- Ravdin PM. A computer program to assist in making breast cancer adjuvant therapy decisions. *Semin Oncol* 1996;23 (1 suppl 2):43-50.
- Ries LAG, Kosary CL, Hankey BF, Miller BA, Edwards BK, eds. *SEER Cancer Statistics Review, 1973-1995*. Bethesda, MD: National Cancer Institute; 1998.
- Robinson CM, Court-Brown CM, McQueen MM, et al. Hip fractures in adults younger than 50 years of age. *Clin Orth Rel Res* 1995;312:238-246.
- Rosenquist CJ, Lindfors KK. Screening mammography beginning at age 40 years. *Cancer* 1998;82:2235-2240.
- Rossner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. *Atherosclerosis* 1984;52:339-346.
- Rutqvist LE, Cedermark B, Glas U, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. *J Natl Cancer Inst* 1991;83:1299-1306.
- Rutqvist LE, Cedermark B, Glas U, et al. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trials. *Int J Radiation Oncology Biol Phys* 1989;16:629-639.
- Rutqvist LE, Cedermark B, Glas U, et al. The Stockholm trial on adjuvant tamoxifen in early breast cancer: Correlation between estrogen receptor level and treatment effect. *Breast Cancer Res Treat* 1987;10:255-266.
- Rutqvist LE, Johansson H, Signomklao T, et al, for the Stockholm Breast Cancer Study Group. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. *J Natl Cancer Inst* 1995;87:645-651.
- Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. *Ann Intern Med* 1997;127:955-965.
- SEER Annual Cancer Statistics Review, 1973-1994. Bethesda, MD: National Cancer Institute; 1997.
- Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. *JAMA* 1996;276:1339-1341.

---

## ...BIBLIOGRAPHY...

- Smith RA, Black BL, Price GW, et al. Legal aspects, legislative effect, cost effectiveness, and barriers to breast cancer screening. *Cancer* 1992;69(suppl):2005-2007.
- Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. *J Natl Cancer Inst* 1993;85:1460-1474.
- Spirtos NM, Schlaerth JB, Gross GM, et al. Cost and quality-of-life analyses of surgery for early endometrial cancer: Laparotomy versus laparoscopy. *Am J Obstet Gynecol* 1996;174:1795-1800.
- Steinberg EP, Javitt JC, Sharkey PD, et al. The content and cost of cataract surgery. *Arch Ophthalmol* 1993;111:1041-1049.
- Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. *J Natl Cancer Inst* 1995;87:417-426.
- Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. *Stroke* 1996;27:1459-1466.
- Terenius L. Effect of anti-oestrogens on initiation of mammary cancer in the female rat. *Eur J Cancer* 1971;7:65-70.
- The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl J Med* 1993;29:673-682.
- Turken S, Siris E, Seldin D, et al. Effects of tamoxifen on spinal bone density in women with breast cancer. *J Natl Cancer Inst* 1989;81:1086-1088.
- US Department of Health and Human Services. *Vital Statistics of the United States, 1991, Volume II Mortality Data, Part A*. Hyattsville, MD: USDHHS; 1996:14-111.
- Vanchieri C. Breast cancer prevention study initiated in Italy. *J Natl Cancer Inst* 1992;84:1555-1556.
- Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. *Lancet* 1998;352:93-97.
- Wakeling AE, Valcaccia B, Newbould E, et al. Non-steroidal antioestrogens: Receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. *J Steroid Biochem* 1984;20:111-120.
- Ward RL, Morgan G, Dalley D, et al. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. *Bone Miner* 1993;22:87-94.
- Weiner JP, Parente ST, Garnick DW, Fowles J, Lawthers AG, Palmer H. Variation in office-based quality: A claims-based profile of care provided to Medicare patients with diabetes. *JAMA* 1995;273:1503-1508.
- Winslow CM, Kosecoff JB, Chassin M, Kanouse DE, Brook RH. The appropriateness of performing coronary artery bypass surgery. *JAMA* 1988;260:505-509.